Skip to main content
Erschienen in: Diabetologia 8/2006

01.08.2006 | Article

Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)

verfasst von: I. M. Stratton, C. A. Cull, A. I. Adler, D. R. Matthews, H. A. W. Neil, R. R. Holman

Erschienen in: Diabetologia | Ausgabe 8/2006

Einloggen, um Zugang zu erhalten

Abstract

Aims/hypothesis

The relative importance of glucose and blood pressure control in type 2 diabetes remains uncertain. We assessed interactive effects of glycaemia and systolic blood pressure (SBP) exposure on the risk of diabetic complications over time.

Subjects, materials and methods

HbA1c and SBP, measured annually for a median of 10.4 years in 4,320 newly diagnosed type 2 diabetic patients from the UK Prospective Diabetes Study (UKPDS), were categorised as updated mean values <6.0, 6.0–6.9, 7.0–7.9 or ≥8.0%, and <130, 130–139, 140–149 or ≥150 mmHg, respectively. Clinical outcomes were UKPDS predefined composite endpoints.

Results

The incidence of the ‘any diabetes-related endpoint’ in the lowest (HbA1c <6.0%, SBP <130 mmHg) and highest (HbA1c ≥8%, SBP ≥150 mmHg) category combinations was 15 and 82 per 1,000 person-years, respectively, and 24 and 120 per 1,000 person-years in a Poisson model adjusted to white Caucasian male sex, age 50 to 54 years and diabetes duration of 7.5 to 12.5 years. Updated mean HbA1c and SBP effects were additive in an adjusted proportional hazards model with risk reductions of 21% per 1% HbA1c decrement and 11% per 10 mmHg SBP decrement. Endpoint rates obtained in the 887 patients randomised in both the glycaemia and hypertension intervention trial arms were consistent with the observational data. Those allocated to both intensive glucose and tight blood pressure control policies had fewer events than those allocated to either policy alone or to neither (p for trend 0.024).

Conclusions/interpretation

Risk of complications in type 2 diabetes is associated independently and additively with hyperglycaemia and hypertension. Intensive treatment of both these risk factors is required to minimise the incidence of complications.
Literatur
1.
Zurück zum Zitat UKPDS Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef UKPDS Group (1998) Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853CrossRef
2.
Zurück zum Zitat Turner R, Cull C, Holman R (1996) UKPDS 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136–145PubMed Turner R, Cull C, Holman R (1996) UKPDS 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 124:136–145PubMed
3.
Zurück zum Zitat Stratton IM, Adler AI, Neil HAW et al (2000) UKPDS 35 Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. BMJ 321:405–412PubMedCrossRef Stratton IM, Adler AI, Neil HAW et al (2000) UKPDS 35 Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes: prospective observational study. BMJ 321:405–412PubMedCrossRef
4.
Zurück zum Zitat UKPDS Group (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36). BMJ 321:412–419CrossRef UKPDS Group (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36). BMJ 321:412–419CrossRef
5.
Zurück zum Zitat Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117PubMedCrossRef Ohkubo Y, Kishikawa H, Araki E et al (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28:103–117PubMedCrossRef
6.
Zurück zum Zitat Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259CrossRef Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355:253–259CrossRef
7.
Zurück zum Zitat Ramsay LE, Williams B, Johnston GD et al (1999) British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 319:630–635PubMed Ramsay LE, Williams B, Johnston GD et al (1999) British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 319:630–635PubMed
8.
Zurück zum Zitat Gaede P, Vedel P, Larsen N, Jensen G, Parving H-H, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef Gaede P, Vedel P, Larsen N, Jensen G, Parving H-H, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef
9.
Zurück zum Zitat UK Prospective Diabetes Study Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890CrossRef UK Prospective Diabetes Study Group (1991) UK Prospective Diabetes Study VIII: study design, progress and performance. Diabetologia 34:877–890CrossRef
10.
Zurück zum Zitat UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713–720 UK Prospective Diabetes Study Group (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317:713–720
11.
Zurück zum Zitat UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713 UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713
12.
Zurück zum Zitat UK Prospective Diabetes Study Group (1994) UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544CrossRef UK Prospective Diabetes Study Group (1994) UK Prospective Diabetes Study XI: biochemical risk factors in type 2 diabetic patients at diagnosis compared with age-matched normal subjects. Diabet Med 11:534–544CrossRef
13.
Zurück zum Zitat Cull CA, Manley SE, Stratton IM, Holman RR, Turner RC, Matthews DR (1997) Approach to maintaining comparability of biochemical data during long-term clinical trials. Clin Chem 43:1913–1918PubMed Cull CA, Manley SE, Stratton IM, Holman RR, Turner RC, Matthews DR (1997) Approach to maintaining comparability of biochemical data during long-term clinical trials. Clin Chem 43:1913–1918PubMed
14.
Zurück zum Zitat Pan WH, Cedres LB, Liu K et al (1986) Relationship of clinical diabetes and asymptomatic hyperglycaemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 123:504–516PubMed Pan WH, Cedres LB, Liu K et al (1986) Relationship of clinical diabetes and asymptomatic hyperglycaemia to risk of coronary heart disease mortality in men and women. Am J Epidemiol 123:504–516PubMed
15.
Zurück zum Zitat Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL (1991) Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 265:627–631PubMedCrossRef Barrett-Connor EL, Cohn BA, Wingard DL, Edelstein SL (1991) Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? JAMA 265:627–631PubMedCrossRef
16.
Zurück zum Zitat Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444PubMedCrossRef Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors, and 12 year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16:434–444PubMedCrossRef
17.
Zurück zum Zitat Hanefeld M, Fischer S, Julius U et al (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577–1583PubMedCrossRef Hanefeld M, Fischer S, Julius U et al (1996) Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 39:1577–1583PubMedCrossRef
18.
Zurück zum Zitat Wilson PW, Cupples LA, Kannel WB (1991) Is hyperglycaemia associated with cardiovascular disease? The Framingham Study. Am Heart J 121:586–590PubMedCrossRef Wilson PW, Cupples LA, Kannel WB (1991) Is hyperglycaemia associated with cardiovascular disease? The Framingham Study. Am Heart J 121:586–590PubMedCrossRef
19.
Zurück zum Zitat UKPDS Group (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes (UKPDS 23). BMJ 316:823–828 UKPDS Group (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes (UKPDS 23). BMJ 316:823–828
20.
Zurück zum Zitat Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L (1989) Impact of cardiovascular risk factors on coronary heart disease among middle aged diabetic men: a general population study. BMJ 299:1127–1131PubMedCrossRef Rosengren A, Welin L, Tsipogianni A, Wilhelmsen L (1989) Impact of cardiovascular risk factors on coronary heart disease among middle aged diabetic men: a general population study. BMJ 299:1127–1131PubMedCrossRef
21.
Zurück zum Zitat Haffner SM, Mitchell BD, Stern MP, Hazuda HP (1991) Macrovascular complications in Mexican Americans with type II diabetes. Diabetes Care 14:665–671PubMedCrossRef Haffner SM, Mitchell BD, Stern MP, Hazuda HP (1991) Macrovascular complications in Mexican Americans with type II diabetes. Diabetes Care 14:665–671PubMedCrossRef
22.
Zurück zum Zitat Moss SE, Klein R, Klein BEK, Meuer SM (1994) The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 154:2473–2479PubMedCrossRef Moss SE, Klein R, Klein BEK, Meuer SM (1994) The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 154:2473–2479PubMedCrossRef
23.
Zurück zum Zitat Manson JAE, Colditz GA, Stampfer MJ et al (1991) A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151:1141–1147PubMedCrossRef Manson JAE, Colditz GA, Stampfer MJ et al (1991) A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 151:1141–1147PubMedCrossRef
24.
Zurück zum Zitat ADVANCE Collaborative Group (2005) ADVANCE—Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 22:882–888CrossRef ADVANCE Collaborative Group (2005) ADVANCE—Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet Med 22:882–888CrossRef
25.
Zurück zum Zitat Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH (eds) (1995) Diabetes in America. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Washington, District of Columbia Harris MI, Cowie CC, Stern MP, Boyko EJ, Reiber GE, Bennett PH (eds) (1995) Diabetes in America. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Washington, District of Columbia
26.
Zurück zum Zitat Shorr RI, Franse LV, Resnick HE, Bari MD, Johnson KC, Pahor M (2000) Glycemic control of older adults with type 2 diabetes: findings from the third national health and nutrition examination survey, 1988–1994. J Am Geriatr Soc 48:264–267PubMed Shorr RI, Franse LV, Resnick HE, Bari MD, Johnson KC, Pahor M (2000) Glycemic control of older adults with type 2 diabetes: findings from the third national health and nutrition examination survey, 1988–1994. J Am Geriatr Soc 48:264–267PubMed
27.
Zurück zum Zitat Stevens R, Adler A, Gray A, Briggs A, Holman R (2000) Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50(Suppl 3):S5–S13PubMedCrossRef Stevens R, Adler A, Gray A, Briggs A, Holman R (2000) Life-expectancy projection by modelling and computer simulation (UKPDS 46). Diabetes Res Clin Pract 50(Suppl 3):S5–S13PubMedCrossRef
28.
Zurück zum Zitat UKPDS Group (2001) The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 101:671–679CrossRef UKPDS Group (2001) The UKPDS Risk Engine: a model for the risk of coronary heart disease in type 2 diabetes (UKPDS 56). Clin Sci 101:671–679CrossRef
Metadaten
Titel
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75)
verfasst von
I. M. Stratton
C. A. Cull
A. I. Adler
D. R. Matthews
H. A. W. Neil
R. R. Holman
Publikationsdatum
01.08.2006
Verlag
Springer-Verlag
Erschienen in
Diabetologia / Ausgabe 8/2006
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0297-1

Weitere Artikel der Ausgabe 8/2006

Diabetologia 8/2006 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.